miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1223-1228

  Yu, Li ^a   Lu, Juan ^a   Zhang, Bao ^b   Liu, Xiong ^a   Wang, Lu ^a   Li, Si Yang ^a   Peng, Xiao Hong ^a   Xu, Xia ^a   Tian, Wen Dong ^a   Li, Xiang Ping ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b School of Public Health and Tropical Medicine   (China)

Author keywords

Enhancer of zeste homolog 2; Metastasis; miR 26a; Nasopharyngeal carcinoma

Indexed keywords

MICRORNA 26A; TRANSCRIPTION FACTOR EZH2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER STAGING; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; METASTASIS; MOUSE; NASOPHARYNX CANCER; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84874407163     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1173     Document Type: Article

References (21)

1. Yu MC and Yuan JM: Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12: 421-429, 2002.
2. Lo AK, Dawson CW, Jin DY and Lo KW: The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol 227: 392-403, 2012.
3. Lee AW, Poon YF, Foo W, et al: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23: 261-270, 1992.
4. Hui EP, Leung SF, Au JS, et al: Lung metastasis alone in naso-pharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101: 300-306, 2004.
5. Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol 4: 199-227, 2009.
6. Li G, Wu Z, Peng Y, et al: MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett 299: 29-36, 2010.
7. Deng M, Tang H, Zhou Y, et al: miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci 124: 2997-3005, 2011.
8. Wong TS, Man OY, Tsang CM, et al: MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through down-regulating c-Myc expression. J Cancer Res Clin Oncol 137: 415-422, 2011.
9. Lu J, He ML, Wang L, et al: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71: 225-233, 2011.
10. Tong ZT, Cai MY, Wang XG, et al: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31: 583-594, 2012.
11. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
12. Alajez NM, Shi W, Hui AB, et al: Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 1: e85, 2010.
13. Liu T, Ding Y, Xie W, et al: An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res 13: 3960-3967, 2007.
14. Li XP, Li CY, Li X, et al: Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-asso-ciated virus-mediated expression of human endostatin. Mol Cancer Ther 5: 1290-1298, 2006.
15. Li W, Yuan Y, Huang L, Qiao M and Zhang Y: Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 96: 187-195, 2012.
16. Dang X, Ma A, Yang L, et al: MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 205: 113-123, 2012.
17. Liu B, Wu X, Wang C, Liu Y, Zhou Q and Xu K: MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 1822: 1692-1704, 2012.
18. Viré E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006.
19. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
20. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transfor-mation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
21. Pietersen AM, Horlings HM, Hauptmann M, et al: EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109, 2008.